Health Trials

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma

To Evaluate the Preliminary Efficacy and Safety/Tolerability of VRT106 Combined with Radiotherapy in Adult Patients with DMG/DIPG

Participants needed: 10
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.Updated: May 15, 2026Locations: 1
Eligibility criteria

Voluntary signing of the Informed Consent Form (ICF), indicating understanding o... [+4]

Individuals with extracranial metastases. [+4]

Read more
Status: Recruiting

A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).

Participants needed: 66
Trial details
Phase: Phase 2, Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.Updated: May 15, 2026Locations: 1
Eligibility criteria

Voluntarily sign the informed consent form (ICF), understand the nature of this... [+5]

Prior receipt of camrelizumab, apatinib, oncolytic viruses, or other gene therap... [+3]

Read more
Status: Recruiting

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.

Participants needed: 42
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.Updated: Jan 2, 2026Locations: 11
Eligibility criteria

Subjects voluntarily participate in the clinical study; fully understand and be... [+7]

Patients with extracranial metastases. [+5]

Read more
Status: Recruiting

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid tumors.

Participants needed: 30
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.Updated: Dec 30, 2025Locations: 3
Eligibility criteria

Subject voluntarily agrees to participate in this study and signs an Institution... [+5]

Subject has received any anti-tumor treatment 4 weeks before using the IMP. [+3]

Read more
Status: Recruiting

A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors

A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors

Participants needed: 12
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.Updated: Jul 18, 2025Locations: 1
Eligibility criteria

Subjects voluntarily participate in the clinical study; fully understand and be... [+8]

Subject has received any antitumor therapy within 4 weeks prior to the first dos... [+4]

Read more
Status: Recruiting

A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors

A Phase I Study of the Safety and Tolerability of M1-c6v1 Administered Via Intravenously for Treatment of Patients With Locally Advanced or Metastatic Solid Tumors

Participants needed: 12
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.Updated: Mar 13, 2025Locations: 3
Eligibility criteria

Subjects must have diagnosis of locally advanced or metastatic solid tumors who... [+5]

Subject has a history of primary or acquired immunodeficient states, leukemia, l... [+3]

Read more